WHY IT MATTERS: If rescheduling leads to FDA-only pathways for legal cannabis, patients currently using state-regulated medical cannabis products could face disruptions in access, changes in available formulations, or higher costs as the market adjusts to new federal compliance requirements. CLINICAL OVERVIEW: The rescheduling of cannabis from Schedule I to Schedule III represents a significant federal policy shift, but it raises complex questions about whether this move truly expands patient access or instead creates a regulatory bottleneck by funneling cannabis into an FDA approval framework that most existing products cannot meet. From a clinical perspective, rescheduling could legitimize cannabis medicine in the eyes of insurers and institutional healthcare systems, yet it risks disrupting the state-regulated markets that currently serve millions of patients.